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Abstract
Antibodies play an increasing pivotal role in both basic research and the biopharmaceutical sector, therefore technology for
characterizing and improving their properties through rational engineering is desirable. This is a difficult task thought to
require high-resolution x-ray structures, which are not always available. We, instead, use a combination of solution NMR
epitope mapping and computational docking to investigate the structure of a human antibody in complex with the four
Dengue virus serotypes. Analysis of the resulting models allows us to design several antibody mutants altering its properties
in a predictable manner, changing its binding selectivity and ultimately improving its ability to neutralize the virus by up to
40 fold. The successful rational design of antibody mutants is a testament to the accuracy achievable by combining
experimental NMR epitope mapping with computational docking and to the possibility of applying it to study antibody/
pathogen interactions.
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Introduction
Improving our understanding of the structural rules governing
antibody/antigen interactions is expected, in the long run, to
accelerate vaccine development, since most modern vaccines aim
to elicit an antibody response, and to help us design better
antibodies for passive immunization or biotechnology applications
such as the production of bio-recognition elements for target
detection. As a proof of concept, we set forth to structurally
characterize the binding of one antibody to the four existing
Dengue Virus (DenV) serotypes and use this information to
rationally alter its immunological properties, eliminating cross-
reactivity and improving its ability to neutralize the virus.
DenV is responsible for 20,000 deaths and 500,000 hospitaliza-
tions annually [1], with economic impact rivaling that of malaria.
Its epidemic activity and geographic expansion are increasing as
climate changes, travel and urbanization create favorable condi-
tions for the mosquito spreading it [2]. No cure or vaccine is
currently available, mostly due to the presence of four serotypes
and to a poorly understood process called Antibody Dependent
Enhancement, where antibodies raised against a previous Dengue
infection facilitate subsequent infection by another serotype [3]. In
addition to its biomedical importance, the presence of related
serotypes and the fact that they are structurally well characterized
both at the protein and viral capsid level make DenV a good
model for the study of antibody/antigen interactions. Although
structural studies often concentrate on the complex between an
antibody and a single serotype, usually the one against which the
antibody is most effective, a comparison of the same antibody
bound to antigens that it can and cannot neutralize may, in fact,
teach us why it is only effective against some of them.
Having isolated a panel of human monoclonal antibodies from
a donor recovered from infection from Dengue Virus serotype 2
(DenV2) [4], we selected and characterized one that would: i) bind
all four DenV serotypes; ii) effectively neutralize only some of them
and iii) bind to the so-called DIII, a small ig-like domain part of the
E protein, whose homodimers are the main component of the viral
surface [5,6,7] and a dominant target for the human antibody
response against DenV [4,8,9,10].
We previously characterized the interaction between DV32.6,
an antibody with the above mentioned properties, and DenV4
[11]. This alone however, cannot explain why DV32.6 can
neutralize the other three serotypes given that the antibody binds
stronger to its epitope on DenV4 rather than DenV1 or DenV3. If
the antibody/antigen interaction were identical in all serotypes,
then the antibody should fail to neutralize DenV1 and DenV3 just
as it fails to neutralize DenV4.
Here we aim to elucidate the structure of DV32.6 in complex
with all the remaining DenV serotypes and exploit the differences
to rationally design mutated antibodies with i) selectively altered
binding specificity and ii) improved ability to neutralize the virus.
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We first use NMR epitope mapping to define the binding site of
DV32.6 on DIII of all four DenV serotypes. We then use this
information to filter computational predictions of the antibody/
antigen complexes. Analysis of the resulting three dimensional
structures proved sufficiently accurate for the rational design of
antibody mutants with selectively altered binding specificity or
improved neutralization properties.
Results
Antibody DV32.6 Binds to All Dengue Serotypes
DV32.6 is part of a panel of human monoclonal antibodies
isolated from a donor recovered from infection by DenV2 [4]. It
binds to DIII of all four DenV serotypes with KD 14569 nM for
DenV1; 760.2 nM for DenV2; 73616 nM for DenV3; 3467 nM
for DenV4 according to SPR (Figure 1). The ability of DV32.6 to
neutralize the virus was assessed by flow cytometry assays
measuring the number of cells infected by DenV vaccine strains
in the presence of different amounts of antibody. There is no direct
correlation between DIII binding affinity and neutralization: the
antibody is more efficient at neutralizing DenV2, DenV1 and
DenV3 despite binding more strongly to DIII of DenV4 (Figure
S1). Association and dissociation rates show no obvious correlation
to the neutralizing activity, either. The approximate concentration
of antibody required to neutralize 50% of the viral activity is 2 mg/
ml for DenV2, 3 mg/ml for DenV3, 4 mg/ml for DenV1 and
.74 mg/ml for DenV4. Incidentally, DV32.6 was isolated from
a patient recovered from DenV2 and is most effective against this
very serotype. Binding assays on isolated DIII allow us to compare
the binding affinity of the antibody for its epitope but the natural
target for the antibody is the full virus, where the surface of DIII is
partially covered by neighbouring protein domains. In contrast to
DIII binding, ELISA performed at 37uC on the full virus show
that binding to DenV4 is not stronger than to other serotypes
(Figure S1). No binding curve is obtained, instead, when
performing ELISA on the full virus at 4uC; this will be later
discussed in the context of the structural data.
NMR Epitope Mapping
Solution NMR spectroscopy was used to characterize, at the
residue level, the epitope (i.e. the region of the antigen that
interacts with the antibody) of DV32.6 on DIII from each DenV
serotype. In a so-called 15N-HSQC experiment, one of the
simplest NMR experiments, each protein residue generates an
individual signal. The position of these signals is sensitive to the
local chemical environment, so much so that 15N-HSQCs are
considered protein fingerprints. We exploit this property to
determine the epitope: when DV32.6 binds to DIII, interface
residues experience a different chemical environment and their
NMR signal changes as a consequence. By comparing the NMR
spectrum of DIII free or in complex with the antibody we can
identify which signals change. Knowing the assignments, i.e.
determining which signal belongs to which antigen residue, we can
therefore determine the residues affected by antibody binding
(Figure S2 and S3). NMR assignments are publicly available for
DIII of three serotypes [12,13,14]. We assigned DIII of DenV3
according to standard techniques. We utilize a purely qualitative
approach: if a signal changes position or disappears, then we know
that the residue generating such signal is affected by antibody
binding. In our experience, a quantitative analysis of the changes is
neither required nor satisfactory in the case of large and poorly
behaved complexes with low spectral quality. Nonetheless, the
accuracy attainable by qualitative analysis even in such compli-
cated cases is sufficient, as we have previously shown for a TCR/
pMHC complex (similar in many ways to our DIII/DV32.6
complexes) that was subsequently validated by an x-ray structure
[15] and in an RNA/protein complex later verified by an NMR
structure [16]. Furthermore, by relying on simple and sensitive
15N-HSQC experiments, or their TROSY equivalent, we can
adopt this approach even for the most difficult cases when more
sophisticated NMR approaches are not suitable. Such NMR
experiments may theoretically offer more information, but they fail
to do so due to lack of sensitivity in the case of our DIII/antibody
complexes.
The NMR signal of approximately 20% of the surface residues
of DIII is perturbed upon binding of DV32.6. No unassigned peak
shows chemical shift changes upon complex formation with the
exception of one signal that presumably belongs to Q316, in the
middle of the epitope. The epitope centers around residues 306–
325 and the antibody footprint shows only slight variation amongst
serotypes (Figure 2a and 2b). It includes residues conserved in all
serotypes, explaining why DV32.6 binds all four of them, and
residues that are not conserved, which are probably responsible for
the different binding and neutralization properties. However,
sequence or structural analysis of the epitope offers no information
on the antibody residues important for interaction. To further
characterize the binding interface we thus predicted the three-
dimensional structure of the complex between DV32.6 and DIII
by computational docking, guided and validated by the NMR
epitope mapping data.
Experimentally Validated Computational Docking
Computational docking predicts the structure of a multi-
molecular complex starting from the separated structures of the
individual components. Experimental structures of DIII from each
serotype are available [6,13,14,17] and were used for docking. We
predicted the structure of antibody DV32.6 by homology
modeling according to the canonical structure method [18].
Although docking a model, thus making a model of a model, is
known to generate problems in protein-protein docking, we and
others have clearly shown that this is not the case for antibodies
[11,18], since they can be modeled with high accuracy and
precision in the vast majority of cases and exceptions are readily
recognized [19]. Briefly, antibody antigen binding loops can adopt
a limited set of conformations constrained by loop length and
presence of specific amino acids at key positions [20]. Exploiting
these constraints yields highly reliable antibody models, except for
the H3 loop that can adopt highly variable conformations. We
thus generated multiple models of DV32.6 [11], differing mainly
in the conformation of the H3 and L3 loop and in the relative
position of the six antigen binding loops. In particular, the H3 loop
extends outwards in some of our models but presents a rather flat
interacting surface in others. The purpose is two-fold: on one hand
by using multiple models we increase the chances that at least one
of them is accurate; on the other hand the ensemble of
conformations may simulate the flexibility available to long
protein loops such as the H3 of DV32.6. We then docked each
antibody model independently to DIII with the program
RosettaDock [21] and validated the results as described in the
methods section. The difference between our approach and
‘‘ensemble docking’’ [22] protocols is that in the latter docks an
ensemble of multiple conformations and uses a scoring function to
select the best model. We, on the other hand, evaluate the docking
of each conformation according to its agreement with the
experimental data. We have previously shown that combining
NMR mapping and docking in this way significantly increases the
accuracy of computational docking [11]. In fact, the initial docking
search we performed failed to generate a so-called ‘‘scoring
Antibody Engineering by NMR Validated Docking
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funnel’’, an ensemble of similar conformations significantly more
accurate than the others according to the docking algorithm.
Without our experimentally validated approach we would not be
able to discriminate amongst a dozen or so solutions recognized as
equally valid by the computational algorithm alone. Further
refinement of the structure in better agreement with the NMR
data (see methods) would often generate two scoring funnels, only
one of which was in agreement with the experimental data.
Interaction of Antibody DV32.6 with the Four Dengue
Serotypes
According to our NMR validated docking predictions, DV32.6
primarily recognizes DIII residues located on adjacent beta
strands, covering between 25 and 28 residues with a buried
surface area between 684 A˚2 (DenV2) and 768 A˚2 (DenV1). These
values are in line with those obtained from x-ray structures of
other antibodies against DIII. Antibody 2H12 has buried surface
area between 491 A˚2 (DenV4) and 652 A˚2 (DenV1). Antibody
1A1D-2 has a larger buried surface of 843 A˚2 and antibody 4E11
buries between 758 A˚2 (DenV3) and 894 A˚2 (DenV1) [23,24,25].
The predicted interface of antibody DV32.6 is dominated by
electrostatic interactions and features several intermolecular
hydrogen bonds and salt bridges. All DIII residues predicted to
be at the interface by the selected docking solutions are also
affected by complex formation in the NMR epitope mapping
experiment.
K310, conserved in all serotypes, is at the center of the interface
and involved in multiple intermolecular contacts. The epitope has
several non-conserved residues, which are probably responsible for
the different binding and neutralization properties of DV32.6.
Indeed, residues 307, 309, 323, 325 and 327 differ among
serotypes and appear to be involved in antibody binding. Residue
309, for instance, is Glu, Val, Lys or Asp in DenV1 to DenV4,
respectively, and it may not be surprising that it has a different
effect on the antibody partner. Perhaps surprisingly, some
conserved DIII residues appear to have different antibody partners
in different serotypes: E311, for instance, interacts with either the
backbone of H-D102 (D102 of the antibody Heavy chain), L-S32
(S32 in the antibody Light chain) or L-S93. This may suggest
conformational plasticity or may very well reflect a limit in the
precision of the computational models. Even if the specific
interactions are wrong, however, the models provide an indication
of which residues are involved in intermolecular contacts. We may
not know if E311 interacts with H-D102, L-S32 or L-S93, for
instance, but we know that it is involved in electrostatic
interactions with the antibody. This level of information was
sufficient to successfully design antibody mutants.
Analyzing the predicted antibody interface (Figure 2c) shows
differences that could be exploited to selectively alter the binding
Figure 1. Antibody DV32.6 binds the four Dengue serotypes with different affinity. SPR sensorgrams showing association and dissociation
of DV32.6 to DIII of each Dengue serotype. The antibody was immobilized on the sensor surface, followed by injection of DIII at the concentrations
indicated in the figure. The line fitted to the experimental data and used to calculate the binding affinities is drawn in gray. KD values are 14569 nM
for DenV1; 760.2 nM for DenV2; 73616 nM for DenV3; 3467 nM for DenV4. Despite binding more weakly to DenV1 and DenV3 than DenV4, the
antibody neutralizes those serotypes better than DenV4.
doi:10.1371/journal.pone.0055561.g001
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properties: the light chain (L1, L2, L3) and H3 antigen binding
loops interact with every serotype; the H2 loop interacts only with
DenV1 and DenV3 and the H1 loop has no contact with any
serotype. Although the total interface area is similar, the light and
heavy chains equally contribute to it in DenV1 and DenV3,
whereas 80% of the interface is formed by the light chain in
DenV2 and DenV4.
Rational Antibody Engineering to Selectively Alter its
Binding Properties
By analyzing the three-dimensional models of the antibody/
DIII complexes we designed several antibody mutants with the
intent of further verifying our computational predictions, altering
the binding properties of the antibody and ultimately improving its
ability to neutralize the virus.
As a first test we aimed to modify the antibody without affecting
its binding to DIII, proving that we can identify and avoid critical
residues. Antibody sequence analysis can easily predict which
residues belong to antigen binding loops and may, therefore,
interact with the antigen. Our models go a step further and can
identify which of these residues are not directly involved in
intermolecular contacts and can thus be mutated without adverse
consequences. We thus selected and mutated a subset of such
residues in each of the three heavy chain antigen binding loops. As
predicted, all the following mutations in the antigen binding loops
didn’t alter the antibody binding properties: H-S104A (Figure 3);
H-T31A; H-S54Q; H-S103V; H-T106A. Binding assays for all the
mutants described in the manuscript are included as figures S4 and
S5.
To further validate our models we then aimed to abolish
antibody binding to all serotypes. Residues L-D50 and L-D51
are predicted to be at the center of the antibody/DenV
interface, forming an intermolecular network of hydrogen bonds
and salt bridges in all serotypes. If our models are correct,
disrupting this network should have a profound effect on the
interface. Indeed, the double mutant L-D50A/D51A completely
abolishes antibody binding (Figure 3). The same result is
obtained when mutating the nearby H-S105D, since the
Figure 2. Antibody DV32.6 interaction with the four Dengue serotypes. NMR epitope mapping results (a, b): residues whose NMR signal is
affected by antibody binding are indicated in red on the sequence (a) and on the surface representation (b) of DIII of each DenV serotype. Residues
for which no NMR information is available are coloured gray in the sequence. The discontinuous epitope shows slight variations amongst serotypes
both in sequence and structure, including some conserved residues and others that are not. The former explain why DV32.6 can bind to all four
serotypes, the latter are likely responsible for the different binding and neutralization properties. Computational docking results (c). Surface
representation of the antigen binding site of DV32.6. Antibody residues predicted to interact with DenV are shown in blue; light and heavy chains are
in light and dark gray, respectively. Both antibody chains contribute to the binding interface in DenV1 and DenV3 whereas only the light chain and
the H3 loop bind to DenV2 and DenV4. Some of the residues mutated to alter the antibody properties in a predictable way (see text) are indicated by
red circles and labelled on DenV1.
doi:10.1371/journal.pone.0055561.g002
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negative charge introduced interferes with the negatively
charged sidechain of L-D50.
Having shown that our approach can identify critical interface
residues, we tackled the much more difficult task of improving the
antibody properties. Generally speaking, increasing antibody
selectivity is a useful exercise to eliminate cross-reactivity with
undesired antigens or to design bio-recognition elements for
specific antigen subtypes. As a proof of concept, we altered the
interaction between DV32.6 and DenV, obtaining an antibody
mutant specific for DenV2 and another that binds only DenV2
and DenV4.
According to our models, residues H-D102/S103, belonging
to the H3 antigen binding loop, point away from the DenV2
antigen. Therefore, mutating them should have no effect on this
serotype. They are, instead, in close proximity of DenV4 and
DenV3. Finally, H-D102 is predicted to form an intermolecular
salt bridge in DenV1. In agreement with this prediction, the H-
D102A/S103A mutant binds DenV2 like the wild-type antibody
but it has severely reduced binding to all other serotypes
(Figure 3).
Since the antibody H2 loop is predicted to interact with DenV1
and DenV3 but not DenV2 and DenV4, we designed the H-S52A
mutant to prevent antibody binding to DenV1 and DenV3 while
leaving the other two serotypes unaltered (Figure 3). This mutant
agrees with the computational prediction that the antibody uses
different binding modes to interact with the serotypes as illustrated
in Figure 2c.
Rational Antibody Engineering to Improve the
Neutralization Properties
The aforementioned mutations are a testimony to our ability to
rationally alter the antibody binding properties and specificity.
Improving the ability of therapeutic products to protect from
infection is, however, the main goal of antibody engineering. As
a proof of concept, analysis of the predicted antibody/antigen
interfaces allowed us to design a mutated antibody 40 times more
efficient than the wild-type in neutralizing DenV1 and another
mutant more efficient against all serotypes, albeit to a lesser extent
(Figure 4).
Our models show that H-S52 is in close proximity to a positively
charged lysine sidechain in DenV1 (Figure 5). Introducing a nearby
negative charge should favor the formation of intermolecular salt
bridges, possibly resulting in improved neutralization properties.
Indeed, the H-S52D antibody is 40 times more efficient in
neutralizing DenV1; the estimated antibody concentration re-
quired to achieve 50% neutralization (EC50) is 0.1 mg/ml for
HS52D and 4.1 mg/ml for wild-type DV32.6 (Figure 4). SPR
indicates that the koff is identical to the wild-type while the kon
improves from 0.9560.0161024 to 4.860.461024 nM21s21,
resulting in a KD of 2862 nM versus 14569 nM. DenV4, where
H-S52D is also a slightly better neutralizer than the wild-type, has
a similar improvement in kon (1.560.1610
24 for the wild-type,
5.361.061024 nM21s21 for H-S52D) and the koff improves as
well (from 5.161.361023 to 0.4760.161023 s21) resulting in KD
of 0.960.04 nM for the mutant versus 3467 nM for the original
antibody.
Figure 3. Rational antibody engineering to selectively alter the binding specificity. Binding assays (ELISA) of representative mutants for
the four DenV serotypes are shown; higher y values correspond to increased antibody binding to DIII. The structural position of these mutants is
indicated in Figure 2c. Wild-type DV32.6 (black) binds to all serotypes and H-S104A does not alter its properties. The L-D50A/D51A mutant cannot
bind to any serotype. The H-D102A/S103A mutant binds to DenV2 and has severely limited binding to the other serotypes. The H-S52A mutant can
only bind to DenV2 and DenV4.
doi:10.1371/journal.pone.0055561.g003
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L-N27, instead, is predicted to be close to a positively charged
region in all serotypes (Figure 5) so introducing a negative charge
should favor the interaction with all of them. An N.E rather than
N.D mutation was introduced because a longer side chain would
get closer to the antigen without creating clashes, according to the
models. Indeed, the L-N27E mutant has improved neutralization
properties for all serotypes (Figure 4). The L-N27E mutant is 3
times more effective on DenV1, 6 on DenV2, 9 on DenV3 and 17
on DenV4 (ratios between the EC50 for wild-type and mutant
antibody). KD is 5 times stronger for DenV1, 23 times stronger for
DenV2, 4 times for DenV3 and 38 times for DenV4. The mutant
has improved Kon in all serotypes whereas the Koff is equal to the
wild type for DenV1 and DenV3. Unfortunately, the effects of the
H-S52D and L-N27E mutations are not additive; the double
mutant shows better neutralization only for DenV3. Apparently,
the interaction cannot tolerate the simultaneous introduction of
two negative charges on the other serotypes.
Discussion
Strategies for optimizing and improving antibody properties are
highly desirable, either to increase their efficacy or to alter their
binding specificity. Generally speaking, abolishing or altering
antibody binding to undesired antigens might confer selectivity to
an otherwise broadly reactive antibody, with practical uses in
avoiding cross-reactivity or designing specific biomarkers (or
biosensors). On the other hand, antibodies that can recognize
only selected serotypes on variable pathogens like Influenza or
Dengue may be engineered to become more broadly reactive.
Antibody optimization can be achieved by randomizing its
sequence with display technologies [26] or by structural analysis
and rational modification of the antibody/antigen interface. This
latter strategy is often neglected and generally thought to require
high resolution crystallographic structures [27], which are not
always available. As a proof of concept, we here show that
structure-based antibody engineering is feasible even without x-ray
information and can be achieved by computational methods
guided and validated by a limited set of rapidly obtained
experimental results. We have previously shown that NMR
mapping can provide an accurate representation of protein-
protein interfaces [15] and that this can greatly increase the
accuracy of computational docking by validating its results [11].
Here we move further ahead by showing that computational
models of antibody/antigen complexes allowed us to rationally
design antibody mutants that improve its properties by i)
disrupting binding only to selected serotypes and ii) improving
virus neutralization up to 40 fold.
Antibody DV32.6, isolated from the serum of a human donor
recovered from DenV2 infection, can efficiently neutralize three of
the four DenV serotypes but binds to all four in the so-called DIII,
the most variable domain of the protein forming the viral surface
Figure 4. Rational antibody engineering for improved virus neutralization properties.We designed two antibody mutants with the intent
of improving its neutralization properties. H-S52D (gray) neutralizes DenV1 40 times more efficiently than the wild-type (black) and L-N27E (violet) is
better than the wild-type in all serotypes, albeit to a lesser extent. Viral neutralization assays are shown; the amount of infected cells (y axis) decreases
at increasing antibody concentration (x axis). In comparison to the wild-type, a lower concentration of mutants is required to neutralize the same
amount of virus.
doi:10.1371/journal.pone.0055561.g004
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and the target of many potent antibodies described so far [4,23].
We identified the epitope of DV32.6 on each serotype at the
residue level with solution NMR spectroscopy and used this
information to guide and validate computational docking simula-
tions yielding three-dimensional models of the antibody/antigen
complexes. Visual analysis of these NMR validated computational
structures allowed us to design a total of 22 antibody mutants, only
4 of which did not have the predicted effect: a testament to the
accuracy of our approach that is unlikely to arise from a random
process. The mutants that did not behave as desired involved:
disruption of a predicted hydrogen bond that did not result in
a detectable loss of binding; a Ser to Gly substitution that
presumably altered the antibody structure and led to total loss of
binding; double substitutions that did not yield the cumulative
effect of the single mutants.
The Rosetta suite is probably the most successful software for
protein folding and engineering [28]. We thus utilized it to
complement our visual structural analysis. In particular, we
attempted to design antibody mutants that would increase the
binding affinity with the RosettaDesign [29] software. However,
the algorithm is biased towards the introduction of hydrophobic
residues at the intermolecular interface and fails to identify the
electrostatic mutations that yield increased virus neutralization in
our case. Unfortunately, we were not able to generate and test the
hydrophobic mutations suggested by RosettaDesign. Hydrophobic
antibodies are often problematic due to aggregation and lack of
specificity (‘‘sticky antibodies’’); moreover, their refolding from
inclusion bodies, if produced in E.Coli, tends to be very difficult.
Automated mutant design by the Rosetta software does not
identify the electrostatic mutations that improve the antibody
properties. Given the mutations, however, we wondered if
a docking algorithm would be able to provide a confirmation of
their efficacy. Judging this is not straightforward since a simple
energetic comparison between wt and mutant by the empiric
Rosetta scoring function is unlikely to provide meaningful results.
We, thus, decided to look for the presence of so-called ‘‘scoring
funnels’’. These are generated when the docking algorithm finds
a large number of similar structures with a pseudo-energy score
significantly better than the other structures. This results in
a funnel shape in a plot of docking score versus structural similarity
(RMSD from a reference structure). Scoring funnels are often
considered an indication of an accurate docking solution, although
exceptions are not uncommon, and in our experience are more
likely to happen when the binding affinity between docking
partners is high. In the case of the DV32.6 mutants there is no
scoring funnel, nor we could detect any other indicator that would
distinguish an effective mutation (e.g. L-N27E, which increases
antibody binding) from an ineffective one (e.g. L-D50A/D51A,
which abolishes binding). On the contrary, we had a scoring
funnel only when docking the L-D50A/D51A mutant.
Software for protein design has leaped forward in recent years
but it is not yet completely reliable. The advantage of human
visual structural analysis, we believe, is that it can detect plausible
intermolecular interactions those requirements may not be directly
satisfied by the model but could be met with limited structural
alterations. In an oversimplified example, an algorithm may
suggest a mutation to form an intermolecular hydrogen bond if the
two required chemical groups are within 3.5 A˚; if the distance is
4.5 A˚, however, it would fail to recognize the possibility. Human
analysis, on the other hand, might recognize that a relatively
minor structural rearrangement would bring the two chemical
groups within bonding distance. This rearrangement might
happen because proteins are flexible or, more simply, because
the position of the chemical groups cannot be ascertained with
high precision in the original structural models. In other words,
human structural analysis can overcome the uncertainty inherent
in computational models, provided that these are sufficiently
accurate to reliably identify interface residues.
Figure 5. Rational antibody engineering, a structural view. a) H-S52 is close to the positive sidechain of K400 in DenV1. Mutating it to the
negatively charged H-S52D favours the interaction and this mutant is 40 fold more effective than the wild type at neutralizing DenV1. The antibody is
shown in green and Denv1 in blue. b) DV32.6 is shown as green cartoon over the electrostatic surface of DenV3; positively charged surfaces are in
blue and negatively charged surfaces in red. L-N27 is close to a positive patch conserved in all serotypes. Introducing a negative charge (L-N27E)
favours the interaction, resulting in improved neutralization properties. The L-N27E substitution was preferred to L-N27D since the longer sidechain
was thought to bring the charged antibody moiety closer to DIII.
doi:10.1371/journal.pone.0055561.g005
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With this approach we produced DV32.6 antibody mutants that
could a) leave binding unaltered, proving that we can identify
residues that are not critical for interaction despite belonging to
the antigen binding loops or b) abolish binding to all serotypes.
More importantly, whereas wild-type DV32.6 binds to all four
DenV serotypes, we could design antibody mutants binding only
to DenV2 or to DenV2 and DenV4. Increasing antibody
specificity is valuable to eliminate unwanted cross-reactivity or to
design bio-recognition elements. If an antibody has therapeutic
purposes, however, one would seek to improve its neutralization
properties, which would have a beneficial effect on dosage and
therapy. It may be argued that if nature was not able to generate
a better antibody, then there is no reason why we should be.
However, individuals generate antibodies against a specific antigen
that may be different from the target of antibody engineering. In
the case of Dengue, for example, an antibody generated against
DenV2 might be rendered more effective against DenV1. Since
the individual from which the antibody was isolated had not been
exposed to DenV1, the immune system would not have been able
to optimize the antibody against this viral strain. Furthermore,
a better antibody may exist in the serum of an immunized
individual but it may simply fail to be successfully isolated.
As a proof of concept, we were able to engineer antibody
mutants up to 40 times more effective than the starting molecule at
neutralizing DenV. These results prove that even when high
resolution x-ray information cannot be easily obtained, antibody/
antigen complexes can be structurally characterized with sufficient
accuracy to allow a fine control of their binding specificity and
immunological properties. Although computational algorithms by
themselves often fail to discriminate inaccurate solutions [18], by
validating them with rapidly obtained NMR epitope mapping
results we could achieve accuracy sufficient for rational mutagen-
esis. It may be argued that sophisticated NMR experiments could
provide more information than the simple 15N-HSQC experi-
ments used in our approach. However, the very simplicity of such
experiments provides reasonably rapid results even in large, poorly
behaved biological molecules where other NMR experiments may
fail due to lack of sensitivity. In fact, even relatively low affinity
complexes that tend to escape successful crystallization can be
investigated by NMR mapping through HSQCs.
In addition to providing the basis for rational mutagenesis,
analysis of the structure of the DV32.6/DIII complexes may be
used to investigate the immunological properties of the antibody.
DV32.6, in fact, is a poor neutralizer of DenV4 despite binding
stronger to its epitope on DIII of DenV4 rather than DenV1 or
DenV3 (KD is 34 nM for DenV4, 74 nM for DenV3 and 146 nM
for DenV1). It may be argued that Kon or Koff, rather than KD,
might be more relevant for neutralization. However, there is no
linear correlation between those and neutralization, either. Koff is
better for DenV4 (5.161.361023 s21, 23.061.161023 s21 and
13.962.061023 s21 for DenV4, DenV3 and DenV1) and Kon is
similar (1.560.161024 nM21s21, 3.160.961024 nM21s21 and
0.9560.0161024 nM21s21 for DenV4, DenV3 and DenV1,
respectively).
Given the same epitope and identical conditions, stronger
binding should lead to stronger neutralization but this is not the
case for DV32.6. One possibility, therefore, is that DenV4 has
a different epitope from the other serotypes. NMR epitope
mapping does not indicate this. The vast majority of the epitope
residues are affected by antibody binding in all serotypes and the
biological significance of those that aren’t is not evident. The
different immunological profile is thus likely to arise from
differences not evident at the epitope level that manifest
themselves on the full viral particle, which the antibody needs to
recognize in order to neutralize the virus.
DV32.6 recognizes a discontinuous epitope centered around the
so-called A strand of DIII of all four Dengue serotypes. This region
is close to the intermolecular interface in the E protein
homodimers that form the surface of mature Dengue virus, with
DIII from one E protein contacting DII of the other unit [30]. On
the viral surface, the DV32.6 epitope is partly covered by DII
residues. Antibodies 1A1D-2 [23] and 4E11 [24] were similarly
shown to bind to partially inaccessible epitopes close to the
DV32.6 binding site. Cryo-EM data shows that1A1D-2 binds to
a virus conformation different from the one determined in the
absence of antibodies. It is likely that DV32.6 sports a similar
mechanism. In fact, steric clashes between DV32.6 and neigh-
bouring E proteins are present when superimposing our models to
the mature structure of the full virus, whereas no clash is detected
when superimposing our models to the structure of the virus in
complex with 1A1D-2. Presumably, structural dynamic of the viral
surface exposes the epitope for a time sufficient for antibody
binding. This theory is in agreement with ELISAs data on DV32.6
binding to the full virus: at 37uC there is sufficient dynamic
movement to uncover the epitope and allow DV32.6 binding; at
4uC, instead, the dynamic process is slowed or altogether halted,
the epitope is not made accessible for a sufficient amount of time
and DV32.6 cannot bind effectively anymore to the virus.
We previously noted that antibody binding to DenV4 is likely to
cause steric clashes on the viral surface, preventing efficient
neutralization. Why is this not the case for the other serotypes?
One possibility is that DV32.6 has less steric clashes on the virion
of DenV1 to 3 and that relieving them requires less extensive, thus
more likely, viral movements than DenV4. Another possibility is
that different viral strains have different extent of dynamic
movements on the viral surface. Indeed, antibody 2H12 was
recently shown to bind a partly inaccessible DIII epitope [25],
although not in the same exact region of DV32.6. Similarly to
DV32.6, 2H12 has the same binding affinity for DIII of all
serotypes (EC50 0.4 nM in ELISA binding assays) but cannot
neutralize DenV2. The authors, Midgley et al., suggest that the
DenV2 virion might be less dynamic than other serotypes [25],
resulting in less frequent exposure of the inaccessible antibody
epitope and less efficient neutralization. In agreement with this
interpretation, DV32.6 binds much stronger to DIII of DenV2
(KD 7 nM) than DenV1 (KD 145 nM), yet it neutralizes both
strains equally well (EC50 is 1.8 mg/ml for DenV2 and 4.1 mg/ml
for DenV1). The decreased binding affinity for DIII of DenV1
would be compensated by the additional rigidity of the virion of
DenV2, resulting in similar neutralization. The same considera-
tions hold true for the L-N27E antibody mutant, that neutralizes
DenV2 and DenV3 equally well despite binding 100 times more
strongly to DIII of DenV2 (KD 0.5 nM for DenV2 and 43 nM for
DenV3, EC50 0.3 mg/ml in both cases).
However, in our case DenV4 would be the least dynamic virion,
since the antibody binds strongly to DIII of this serotype but fails
to neutralize the virus, suggesting that the epitope is seldom
accessible on the viral surface. Midgley et al. do not describe
a similar property for DenV4, although this serotype is less
efficiently neutralized than DenV1 despite having similar binding
affinity. One difference between the previously reported work and
ours is that whereas both research teams use the same viral strains
for DenV1 and DenV2, there are two aminoacid differences in
DenV4 (L356F and N383D). Whether this is sufficient to justify
a different viral flexibility is debatable.
Overall, the structural flexibility of Dengue viral strains remains
largely unexplored. It is not clear, for instance, if it is exclusively an
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intrinsic property of the virion or if the antibodies can affect it.
Antibody binding to one E protein on the viral surface, for
instance, may distort the ordered structure of the virus and
provoke a chain reaction making the epitopes on the other E
proteins more readily accessible.
Conclusions
Structural characterization of antibody/antigen complexes
relies almost exclusively on x-ray information that may not always
be available. Computational docking is emerging as an affordable
alternative but it often fails to discriminate inaccurate solutions.
We have shown that this problem can be alleviated by rejecting
computational solutions that do not agree with a limited set of
rapidly obtained experimental data. These may arise from viral
escape mutants, peptide mapping or antigen mutagenesis; NMR
epitope mapping, however, is a powerful tool for the detailed
characterization of antibody binding sites with the potential to
identify the epitope of several antibodies in a matter of hours, once
assignment is available. We have shown that combining docking
and NMR epitope mapping yields results sufficiently accurate for
the rational modification of the antibody properties even in the
absence of high resolution x-ray information. For antibody
docking we have had good success with RosettaDock [21] but
other programs like HADDOCK [31] are equally good. We
believe that NMR validated computational docking can find
widespread use in the structural characterization of antibody/
antigen interactions, with implications for basic research, patent-
ing purposes, screening and selection of candidate molecules as
well as rational optimization of their binding and immunological
properties.
Materials and Methods
Isolation of Human Monoclonal Antibody
Briefly, memory B cells were isolated from the blood serum of
a donor recovered from DenV2 infection and immortalized with
EBV as previously described [4]. The study protocol was approved
by the Scientific and Ethical Committee of the Hospital for
Tropical Diseases and the Oxford Tropical Research Ethical
Committee. Written informed consent was provided. B cell clones
were then tested for specificity by staining of Dengue infected cells
and ELISA with recombinant E protein.
Antigen and Antibodies Production and Purification
The sequence of DIII from each serotype was identical to that of
the viral strains used for the binding and neutralization assays.
DIII domains from E protein of each Dengue serotype were
expressed in E. coli Rosetta cells with a pET21 vector (Novagen),
induced at OD600 = 0.7 and harvested after 3 hours. After
sonication and centrifugation, the pellet was repeatedly washed
and centrifuged in sodium phosphate buffer pH 7.2, 1 M NaCl,
1 M urea and 1% Triton X-100. The pellet was finally
resuspended in the same buffer with 8 M urea (buffer A).
Following addition of 0.2% PEI and centrifugation, 65%
ammonium sulphate was added to the supernatant. After
centrifugation, the pellet was resuspended in buffer A and dialyzed
for 3 days against 20 mM sodium phosphate buffer, 150 mM
NaCl, 200 mM arginine, adding small amounts of pellet every 8
hours. DIIIs were finally purified on a superdex-75 size exclusion
column (GE) with the buffer used for NMR and concentrated with
Vivaspin concentrators (Sartorius). 15N and 13C labeled DIIIs,
used for NMR experiments, were expressed in M9 minimal media
using aptly labeled nutrients (NH4Cl and glucose) as sole source of
nitrogen and carbon. DIIIs were proven to be correctly folded by
NMR 15N-HSQC experiments.
DV32.6 from B-cell culture supernatant was purified by
protein-A affinity chromatography followed by size-exclusion
according to standard protocols. The Fab fragments utilized for
NMR experiments were obtained by enzymatic digestion with
immobilized papain (Pierce) for 8 hours at 37uC, followed by
dialysis, protein-A affinity and finally size exclusion chromatogra-
phy against the NMR buffer. Recombinant wild-type antibody
and mutants were expressed in HEK293T cells and purified as
before. All samples were freshly prepared and mixed immediately
before the required experiments.
NMR Epitope Mapping
NMR epitope mapping experiments were conducted on the
complex between DIII of each serotype and either full DV32.6
(1:2 ratio to DIII) or its antigen binding fragment (Fab, 1:1 ratio to
DIII). Using the full antibody is more problematic for NMR due to
its larger size but the enzymatic digestion required to obtain the
Fab fragments comported a significant loss of material and, thus,
sample dilution. Use of Fab fragments tended to provide better
NMR results. TROSY versions or simple HSQCs experiments
offered comparable sensitivity, they were both tested on each
sample and the best one was chosen for the final experiment.
Typical acquisition time was 30 minutes for free DIIIs and 18–24
hours for the complex at a temperature of 298 K. Typical
concentration was around 0.25 mM in 20 mM NaPhosphate
pH6, 50 mM NaCl. In a typical experiment, a 15N-HSQC
spectrum of DIII from one serotype was recorded and a second
spectrum was recorded after addition of the Fab of DV32.6. The
two spectra were visually compared and residues with different
signal in the free and bound form were identified. Knowing the
assignment, i.e. which protein residue corresponds to each NMR
signal, DIII residues affected by DV32.6 binding were localized.
NMR assignments of DIII from DenV1, DenV2 and DenV4 are
publically available [12,13,14]. We assigned the backbone atoms
of DIII of DenV3 with HNCACB and 15N-NOESY-HSQC
experiments according to standard techniques. Spectra were
recorded on Bruker 750 MHz and 800 MHz instruments
equipped with cryoprobe and analyzed with the program Sparky
[32].
Antibody Modeling and Docking
DV32.6 was modelled according to the canonical structure
method with the programs PIGS [19] and RosettaAntibody [33]
as previously described [18]. 11 models with different H3 loop
conformations were generated and independently used for dock-
ing. The structure of DIII from all serotypes is publically available
[6,13,14,17] and was used for docking.
Docking was performed using RosettaDock 2.3 as previously
described [11]. In summary, a given antibody model was docked
to DIII of one serotype; amongst the thousands of computationally
generated complexes (typically 15,000), the one in better
agreement with the NMR epitope mapping data was selected
and further refined. If an antigen residue is in contact with the
antibody in a docking decoy and is also affected by antibody
binding in the NMR mapping experiment, then it is considered
a valid contact. If it is not affected by antibody binding according
to the NMR data then it is considered a violation. We select the
docking decoys that maximize the number of valid contacts while
avoiding violations. An antigen residue is defined ‘‘in contact’’ if
either its N or H backbone atoms are within 7 A˚ of any antibody
atom. This criterion proved to yield the most accurate results in
extensive docking back-calculations of protein-protein complexes
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with known experimental structure and available NMR mapping
information. By repeating the procedure for each of the 11
antibody starting models we obtained 11 putative complex
structures. Not all of them equally satisfied the NMR epitope
mapping data, so we finally retained only those complexes that
had no significant disagreement with the experimental data and
included all of them in the structural analysis. Computational
models were discarded if the number of violations was greater than
1 or if the antibody showed extensive contacts with the antigen
outside the canonical interaction regions (antigen binding loops
and neighboring area). Amongst the remaining structures, those
with a higher number of valid contacts were preferred. This was
repeated for DIII of each Dengue serotypes. A table summarizing
the docking and NMR epitope mapping results is offered as Table
S1.
Antibody Engineering
Antibody mutations were designed by visual analysis of the
experimentally validated computational models. Single-point
mutations were generated by site-directed mutagenesis of a vector
encoding the wild-type antibody sequence using the QuikChange
site-directed mutagenesis kit (Stratagene). The introduction of the
desired mutations was confirmed by DNA sequencing. The PCR
products were transformed into XL10-Blue supercompetent E.
coli cells (Stratagene) and the plasmids purified according to
standard techniques and transferred into HEK293T cells for
antibody production.
Binding and Neutralization Assays
All the neutralization and binding assays reported here were
conducted on the wild-type antibody purified from immortalized
B-cells isolated from the blood of a human donor, on the wild-type
antibody cloned in HEK293T cells and on the mutated antibodies.
Each measurement was conducted in duplicate, repeated 3 times
and reported as the average of the resulting values. Results are
normalized by considering as 100% the maximum point reached
by the wild-type antibody, included as a reference in all
experiments. EC50 were calculated as the midpoint transition in
the s shaped curves after line fitting according to standard
procedures.
Binding assays: 96-well ELISA plates were coated at 4uC with
recombinant DIII or purified virus from DenV1-4. After washing
and blocking, antibodies were added for 1 hr at 37uC. After
further wash, bound antibodies were revealed using goat anti-
human IgG coupled to alkaline phosphatase (Jackson Immunor-
esearch).
The ability of DV32.6 to neutralize the virus was assessed by
flow cytometry assays measuring the number of VERO or RAJI
cells infected by DenV vaccine strains in the presence of different
amounts of antibody [4]. Different antibody concentrations were
pre-incubated with DenV attenuated virus and used to infect
VERO or RAJI cells. The percentage of infected cells was
determined by fluorescence-activated cell sorting using standard
procedures, staining the cells with mouse mAb 4G2 (ATCC, D1-
4G2-4-15).
Surface Plasmon Resonance Binding Assays
The affinity of DV32.6 for DIII of the four Dengue serotypes
was determined at 25uC with a ProteOn XPR-36 instrument (Bio-
Rad). The antibodies (concentration 150 nM) were immobilized
on the surface of a GLM sensor chip through standard amine
coupling. DIII was injected at a flow rate of 100 ml/min (contact
time, 1 min) at different concentrations (300, 150, 50, 25 and
10 nM, running in parallel on separate channels); dissociation was
followed for 15 min. Analytes responses were corrected for
responses from buffer-only injection both on a channel with
antibody immobilized and on a channel with no antibody
immobilized. Curve fitting and data analysis were performed with
Bio-Rad ProteOn Manager software (version 3.1.0.6).
Supporting Information
Figure S1 DV32.6 has a stronger binding affinity for its
epitope on DIII of DenV4 than for the other serotypes
(panel a) but it is less efficient at neutralizing it (panel
c). a) Binding assay (ELISA) for wt DV32.6 on DIII. The antibody
concentration is on the x axis and increased y values correspond to
increased binding. DIII from each Dengue serotype was
immobilized on a surface in the presence of different amounts of
antibodies as described in the methods. Binding appears stronger
for DenV4 than other serotypes. The experiment was done in
duplicate and repeated 3 times. b) Binding assay (ELISA) for wt
DV32.6 on the full virus at 37uC. The purified virus from each
serotype was immobilized on a surface in the presence of different
amounts of antibodies. In contrast to the results of isolated DIII,
binding to DenV4 is not stronger than to other serotypes. In fact,
the binding curve does not reach plateaux in DenV4 at the tested
antibody concentrations. The experiment was done in triplicate. c)
Viral neutralization assay; the amount of infected cells (y axis)
decreases at increasing antibody concentration (x axis). A higher
amount of antibody is required to neutralize DenV4.
(TIF)
Figure S2 15N HSQC spectra of DIII of the four Dengue
serotypes free (blue) and in complex with antibody
DV32.6 (red). Residue V324 is affected by complex formation
and shows chemical shift changes in DenV1, DenV3 and DenV4
but not DenV2.
(TIF)
Figure S3 15N HSQC spectra of DIII of the four Dengue
serotypes free (blue) and in complex with antibody
DV32.6 (red). Residue K310 shows chemical shift changes upon
complex formation in DenV4 and DenV1 (smaller changes). The
peak corresponding to the bound state disappears in DenV2 and
DenV3, revealing that the residue is affected by antibody binding.
(TIF)
Figure S4 Binding assay (ELISA) for all the antibody
mutants designed to alter its properties in a predictable
manner and mentioned in the main text. The antibody
concentration is on the x axis; increased y values correspond to
increased binding. DIII from each Dengue serotype was
immobilized on a surface in the presence of different amounts of
antibodies as described.
(TIF)
Figure S5.
(TIF)
Table S1 NMR validation and docking results for the
DV32.6/DIII complexes chosen as representative for
each different antibody homology model used for dock-
ing (Model1 to Model10 and PIGS). Models in agreement
with the NMR epitope mapping data and chosen as final result for
the structural analysis (see main text) are highlighted in green. If an
antigen residue is in contact with the antibody in the computa-
tional model and is affected by complex formation in the NMR
epitope mapping experiments then it is considered a ‘‘valid
contact’’. If it is in contact in the computational model but is not
affected in the NMR epitope mapping experiment then it is
Antibody Engineering by NMR Validated Docking
PLOS ONE | www.plosone.org 10 February 2013 | Volume 8 | Issue 2 | e55561
considered a violation. The column ‘‘Valid-violations’’ indicates
these numbers for each model. ‘‘Rosetta score’’ is the score
calculated by the Rosetta-Dock scoring function, the lower the
better; it is not sufficient by itself to discriminate incorrect models.
‘‘Rosetta ranking’’ indicates the rank, by score, assigned by
Rosetta-Dock. A ranking of 1 means that the structure is the best
scoring amongst the thousands of decoys generated in a typical
docking run. Without NMR epitope mapping information one
would have to rely entirely on the computational scoring function.
In our case, instead, lower ranking models better satisfy the NMR
epitope mapping information.
(PDF)
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